

Elért eredmények:

1. Publikációk:

1.1. nemzetközi folyóiratban megjelent közlemény: 41 (IF: 147,4).

1.2. részletes lista: <http://www.mtakpa.hu/kpa/kereso/slist.php?kozid=17204>

Közlemények:

PUBLIKÁCIÓS JEGYZÉK:

Cikkek:

Szerzők:	Cím:	Folyóirat	Év	IF
1 Heemann U, Azuma H, Hamar P , Schmid C, Tilney N, Philipp T:	Mycophenolat mofetil inhibits lymphocyte binding and the upregulation of adhesion molecules in acute rejection of rat kidney allografts.	Transpl Immunol	1996 4: 64-67	0
2 Becker G, Witzke O, Baltés A, Hamar P , Philipp Th, Heemann U:	Diltiazem minimizes tubular damage due to FK506-mediated nephrotoxicity following ischemia and reperfusion in rats.	Transpl Immunol	1996 4: 68-71	0
3 Schleimer K, Szabó A, Müller V, Hamar P , Heemann U, Eigler FW:	Effect of the ACE inhibitor enalapril on development of chronic rejection after orthotopic rat kidney transplantation.	Langenbecks Arch Surg	1997 114: 279-83	0,128
4 Hamar P , Müller V, Kohnle M, Witzke O, Albrecht KH, Philipp Th, Heemann U:	Metabolic factors have a major impact on kidney allograft survival.	Transplantation	1997 64: 1135-9	3,441
5 Peti Peterdi J, Hamar P , Kovács G, Rosivall L:	Direct in vivo measurement of gastric microvascular pressures in the rat.	Microvasc Res	1998 55:223-229	1,496
6 Peti Peterdi J, Kovács G, Hamar P , Rosivall L:	Hemodynamics of the gastric microcirculation in rats.	Am J Physiol: Heart	1998 275:H 1404-14010	3,077
7 Müller V, Hamar P , Szabó Attila, Knust E, Vogelsang M, Heemann U:	Effect of Mycophenolate Mofetil on the in-vivo infiltration of lymphocytes in the rat remnant kidney.	Transplant P	1998 30:982	0,74
8 Hamar P , Peti Peterdi J, Rázga Zs, Kovács G, Heemann U, Rosivall L:	Coinhibition of immune and renin-angiotensin systems, reduces the pace of glomerulosclerosis in the rat remnant kidney	J Am Soc Nephrol	1999 10: s234-238	6,182
9 Müller V, Hamar P , Szabó A, Vogelsang M, Philipp Th, Heemann U:	In-vivo migration of lymphocytes in chronically rejecting rat kidney allografts.	Transplant Int	1999 12: 145-151	1,599
10 Heemann U, Szabó A, Hamar P , Müller V, Witzke O, Viklicky O, Philipp Th:	LPS pretreatment protects from renal ischemia/reperfusion injury: possibly connected to an IL-6 dependent pathway.	Am J Pathol	2000 156: 287-93	6,971
11 Hamar P , Liu S, Viklicky O, Szabó A, Müller V, Heemann U:	Cyclosporine A and Azathioprine are equipotent in chronic kidney allograft rejection	Transplantation	2000 69: 1290-5	4,035

12	Szabó A, Lutz J, Schleimer K, Antus B, Hamar P , Philipp Th, Heemann U:	Effect of ACE inhibition on growth factor mRNA in chronic renal allograft rejection in the rat.	Kidney Int	2000 57: 982-991	4,371
13	Losonczy G, Kriston T, Szabo A, Muller V, Harvey J, Hamar P , Heemann U, Baylis C.	Male gender predisposes to development of endotoxic shock in the rat.	Cardiovasc Res	2000 47:183-91.	3,783
14	Hamar P , Peti Peterdi J, Szabó A, Becker G, Flach R, Rosivall L, Heemann U:	Interleukin-2-dependent mechanisms are involved in the development of glomerulosclerosis after partial renal ablation in rats.	Exp Nephrol	2001 9: 133-141	1,881
15	Hamar P , Szabó A, Müller V, Heemann U:	Involvement of interleukin-2 and growth factors in chronic kidney allograft rejection in rats.	Transplant P	2001 33(3): 2160-2.	0,568
16	Hamar P , Szabó A, Müller V, Heemann U:	The involvement of activated T-cells and growth factor production in the early and late phase of chronic kidney allograft nephropathy in rats	Transplant Int	2002 15: 446-454	2,52
17	Antus B, Hamar P , Kökény G, Szollosi Z, Mucsi I, Nemes Z, Rosivall L:	Estradiol is nephroprotective in the rat remnant kidney.	Nephrol Dial Transpl	2003 18: 54-61	2,607
18	Bagi Zs, Hamar P , Antus B, Rosivall L, Koller Á:	Chronic renal failure leads to reduced flow-dependent dilation in isolated rat skeletal muscle arterioles due to lack of NO mediation	Kidney Blood pressure Res	2003 26(1): 19-26	1,025
19	Su F, Hu X, Jia W, Gong C, Song E, Hamar P	Glutathion S Transferase p indicates chemotherapy resistance in breast cancer	J Surg Res	2003 113:102-108	1,735
20	Gross ML, Adamczak M, Rabe T, Harbi NA, Krtil J, Koch A, Hamar P , Amann K, Ritz E	Beneficial effects of estrogens on indices of renal damage in uninephrectomised SHRsp rats	J Am Soc Nephrol	2004 15: 348-58	6,644
21	Yao H, Song E, Chen J, Hamar P	Expression of FAP-1 by human colon adenocarcinoma: implication for resistance against Fas-mediated apoptosis in cancer	Br J Cancer	2004 ; 91: 1718-25	3,742
22	Hamar P , Song E, Kökény G, Chen A, Ouyang N, Lieberman J:	Short interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury	P Natl Acad Sci USA	2004 101: 14883–14888	10,452
23	Lutz J, Yao Y, Song EW, Antus B, Hamar P , Liu S, Heemann U:	Inhibition of Matrix Metalloproteinases During Chronic Allograft Nephropathy in Rats.	Transplantatio n	2005 27;79: 655-661	3,879
24	Hamar P , Lipták P, Heemann U, Iványi B	Ultrastructural analysis of the fisher to lewis rat model of chronic allograft nephropathy	Transplant Int	2005 18: 863-870	1,797

25	Bagi Zs, Hamar P , Kardos M, Koller Á:	Lack of Flow Mediated Dilation and Enhanced Angiotensin II-induced Constriction in Skeletal Muscle Arterioles of Lupus-Prone Autoimmune Mice	Lupus	2006 15: 1-9	2,4
26	Rácz Zs, Hamar P ,	Can siRNA technology provide the tools for gene therapy of the future?	Curr Med Chem (CMC)	2006 13 (19): 2299-2307	4,904
27	Huber W , Eckel F , Hennig M , Rosenbrock H , Wacker A , Saur D , Sennefelder A , Hennico R , Schenk C , Meining A , Schmelz R , Fritsch R , Weiss W , Hamar P , Heemann U , Schmid RM .	Prophylaxis of contrast material-induced nephropathy in patients in intensive care: Acetylcysteine, theophylline, or both? A randomized study	Radiology	2006 239(3), 793-804	5,377
28	Hamar P , Kökény G, Lipták P, Krtíl J, Adamczak M, Aman K, Ritz E, Groß ML	The combination of ACE inhibition plus sympathetic denervation is superior to ACE inhibitor monotherapy in the rat renal ablation model	Nephron (Exp Nephrol)	2007 105:124-136	1,394
29	Kökény G, Godó M, Nagy E, Kardos M, Kotsch K, Casalis P, Bodor C, Rosivall L, Volk HD, Zenclussen AC, Hamar P	Skin disease is prevented but nephritis is accelerated by multiple pregnancies in autoimmune MRL/lpr mice	Lupus	2007 16(7):465-77.	2,248
30	Zenclussen AC, Kökény G, Thimm O, Sollwedel A, <i>Godó M</i> , Casalis PA, Zenclussen ML, Volk HD, Hamar P :	Flare of renal lupus during murine pregnancy is due to increased IgG and C3 glomerular deposition but is independent of Treg function	Reprod Biomed Online	2008 17:114-26.	2,954
31	Rácz Zs, Hamar P ,	RNA interference in research and therapy of renal diseases	Contrib Nephrol. Basel, Karger,	2008 159: 78–95	1,83
32	<i>Godó M</i> , <i>Sessler T</i> , Hamar P	Role of invariant natural killer T (iNKT) cells in systemic lupus erythematosus	Curr Med Chem (CMC)	2008 15: 1778-87	4,823
33	<i>Németh Z</i> , <i>Kökény G</i> , <i>Godó M</i> , <i>Mózes M</i> , Rosivall L, Groß ML, Ritz E, Hamar P	Increased renoprotection with ACE inhibitor plus aldosterone antagonist as compared to monotherapies - the effect on podocytes	Nephrol Dial Transpl	2009 (12): 3640-51.	3,568
34	Hamar P , Wang M, <i>Godó M</i> , <i>Kökény G</i> , Ouyang N, Heemann U	Lupus nephritis reoccurs following transplantation in the lupus prone mouse.	Lupus	2010 19:175-81	2,244
35	<i>Kökény G</i> , <i>Németh Z</i> , <i>Godó M</i> , Hamar P	The Rowett rat strain is resistant to renal fibrosis	Nephrol Dial Transpl	2010 25:1458-62	3,568

36	Rácz Zs, Nagy E, Rosivall L, Szebeni J, Hamar P	Sugar-free, glycine-stabilized intravenous immunoglobulin prevents skin but not renal disease in the MRL/lpr mouse model of systemic lupus.	Lupus	2010 19: 599-612	2,244
37	Buday A, Órsy P, Godó M, Mózes M, Kökény G, Lacza Zs, Koller A, Ungvári Z, Gross ML, Benyó Z, Hamar P	Elevated systemic TGF-beta impairs aortic vasomotor function through activation of NADPH oxidase driven superoxide production and leads to hypertension, myocardial remodeling and increased plaque formation in apoE ^{-/-} mice.	Am J Physiol Heart Circ Physiol	2010 299: H386-95.	3,643
38	Kaucsár T, Rácz Zs, Hamar P	Post-transcriptional gene-expression regulation by micro RNA (miRNA) network in renal disease	Adv Drug Delivery Rev	2010 30: 1390-401.	11,957
39	Stokman G, Qin Y, Rácz Zs, Hamar P , Price LS	Application of siRNA in targeting protein expression in kidney disease	Adv Drug Delivery Rev	2010 30: 1378-89.	11,957
40	Rácz Zs, Godó M, Hamar P	No interferon response in mice following systemic siRNA treatment	Nucleic Acid Ther.	2011 21: 215-24.	2,986
41	Fugmann T, Borgia B, Révész Cs, Godó M, Forsblom C, Hamar P , Holthöfer H, Neri D, Roesli C	Proteomic identification of accessible proteins in a rat model of diabetic nephropathy reveals vanin-1 as a marker of kidney damage	Kidney Int	2011 80: 272-81.	6,193

Hazai folyóiratban:

1	Hamar P , Heemann U, Rosivall L:	Az alloantigén független tényezők szerepe a transzplantált vese krónikus kilökődésében.	Hyperton Neph	1998 2: 59-66
2	Hamar P , Szabó Attila, Kovács Gergely, Kökény Gábor, Heemann Uwe, Rosivall László:	Az interleukin-2 által közvetített mechanizmusok szerepet játszanak transzplantált patkányvese chronicus kilökődésében.	Hyperton Neph	1999 3: 93-100
3	Szabó A, Müller V, Schleimer K, Fekete A, Hamar P , Antus B, Reusz G, Heemann U	Az angiotenzin konvertáló enzim gátló enalapril csökkenti a növekedési faktorok mRNS-expressióját a vestranszplantátum chronicus kilökődése során patkányban	Hyperton Neph	2001 5: 44-51
4	M Adamczak, P Hamar , E Ritz	The kidney as a cause and a target of hypertension	Hyperton Neph	2003 7: 153-161
5	Hamar P , Markovics Gy, Rugonfalvi KSz,	Az ezerarcú endothel	Érbetegségek	2003 X (4): 103-110

Szilágyi E:

6	Hunyadi J, Bihari I, Nagy I, Török Zs, Hamar P	Krónikus sebek kezelése a gyógyulás különböző fázisaiban	Érbetegségek	2004 XI(2): 57-65
7	Rácz Zs, Hamar P	SiRNA technológia, a jövő génterápiája? [SiRNA technology, the gene therapy of the future?]	Orvosi Hetilap	2008 149(4):153-9.
8	Hamar P	A tápcsatorna betegségeinek laboratóriumi diagnosztikája	Orovsképzés	2011 suppl.3, 83: 242-243
9	Rácz Zs, Kaucsár T, Hamar P	The huge world of small RNAs: regulating networks of microRNAs	Acta Physiologica Hungarica	2011 98: 243-254

2. Találmányok:

- 2.1. Subject of the patent: [Method for treating and preventing ischemia-reperfusion injury using rna interfering agent](#). Assignee: Immune Disease Institute Inc (Boston, Ma). **Inventor:** Lieberman Judy (Brookline, Ma), Hamar Peter (Budapest, Hu), Song Erwei (Guang Dong, Cn). US.Apps - 20080227733

3. Elnyert pályázatok, támogatások (utolsó 5 év) (év, cím, támogató, nyilvántartási szám):

- 3.1. 2010-2014 Micro RNS hálózatok szabályozó szerepének vizsgálata akut veseelégtelenségben OTKA - K 81972
- 3.2. 2009-2011 Micro RNS hálózatok szabályozó szerepének vizsgálata akut veseelégtelenségben ETT - 07-011/ 2009
- 3.3. 2008-2011 The role of TGF-beta and its intracellular signaling in uremic atherosclerosis OTKA - NF 69278
- 3.4. 2007-2008 The role of lymphangiogenesis in chronic allograft nephropathy OMFB/Tet - ÖAD HU/08/2007
- 3.5. 2007-2008 A kombinált aldosteron és RAS gátlás hatása 5/6 nefrektómia modellben OMFB/Tet - DAAD D/06/05860
- 3.6. 2006-2008 „Einfluß der kombinierten Blockade von RAS und Mineralkortikoid Rezeptor auf die Progression am Modell der subtotalen Nephrektomie - morphologische und molekularbiologische Untersuchungen" Else Kröner-Fresenius Stiftung P50/05//A64/05//F01
- 3.7. 2005-2008 RNAi to limit kidney ischemia/reperfusion injury FIRCA (Fogarthy International and Cooperative Projects) R03 - TW007069-01A1
- 3.8. 2005-2009 Vese ischemia/reperfúziós károsodásának gátlása RNS interferencia segítségével OTKA - T049022